

Controlled Hypotension in Rhinoplasty Surgery: Mechanisms, Techniques, and Clinical Considerations; A Narrative Review

Hamidreza Azizi Farsani¹, Zahra Abbasi^{2,3}, Hasanali Ahmadi⁴, Mohamad Ali Asadi^{2,3**}, Sogol Asgari^{2*}

1. Department of Anesthesiology, School of Medicine, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2. Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3. Department of Otorhinolaryngology, School of Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4. Department of Anesthesiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Article Info

Article Note:

Received: July 2025

Accepted: July 2025

Publish Online: August 2025

Corresponding Author:

Dr. Sogol Asgari

Email:

drasgari98429@gmail.com

**Co-Correspond Author:

Dr. Mohamad Ali Asadi

Email:

Dr.ma.asadi2024@gmail.com

Keywords:

Hypotension;

Rhinoplasty;

Clinical considerations.

Abstract

Background: Controlled hypotension is a commonly employed anesthetic technique in rhinoplasty aimed at reducing intraoperative bleeding and improving surgical field visibility. Despite its widespread use, there remains variability in the choice of pharmacological agents and clinical protocols.

Aim: This narrative review provides a comprehensive overview of the mechanisms, pharmacological techniques, and clinical considerations involved in controlled hypotension for rhinoplasty.

Methods: Key studies, clinical trials, and systematic reviews published on controlled hypotension agents including dexmedetomidine, esmolol, magnesium sulfate, and remifentanyl were analyzed and synthesized.

Results: Controlled hypotension effectively decreases intraoperative blood loss and enhances surgical conditions. Dexmedetomidine offers stable hemodynamics with sedative and analgesic benefits, while esmolol and remifentanyl allow rapid and titratable blood pressure control. Magnesium sulfate serves as an adjunct with vasodilatory and neuroprotective effects. Careful patient selection and continuous hemodynamic monitoring are critical to minimize adverse events.

Conclusion: When applied judiciously, controlled hypotension is a valuable strategy in rhinoplasty anesthesia, improving surgical outcomes and patient safety. Future research should focus on optimizing drug combinations and protocols to further enhance efficacy and minimize risks.

Conflicts of Interest: The Authors declare no conflicts of interest.

Please cite this article as: Azizi Farsani H, Abbasi Z, Ahmadi H, Asadi MA, Asgari S. Controlled Hypotension in Rhinoplasty Surgery: Mechanisms, Techniques, and Clinical Considerations; A Narrative Review. J Otorhinolaryngol Facial Plast Surg 2025;11(1):1-8. <https://doi.org/10.22037/orlfps.v11i1.50174>

Introduction

Rhinoplasty is a popular cosmetic surgery that often presents challenges related to significant bleeding due to the rich vascular network of the nasal tissues. Excessive bleeding can reduce the surgeon's visibility, prolong operative time, and increase postoperative complications, which may compromise the overall surgical outcome (1). Therefore, effective management of bleeding is essential to improve both surgical conditions and patient safety. Controlled hypotension is a well-established anesthetic

technique that aims to deliberately lower the patient's blood pressure to a predefined safe level, thereby reducing intraoperative blood loss and enhancing the quality of the surgical field (2). Achieving controlled hypotension requires careful selection of pharmacological agents alongside vigilant monitoring of hemodynamic parameters.

Various medications have been evaluated for their efficacy in inducing controlled hypotension during rhinoplasty and other nasal

surgeries. Dexmedetomidine, esmolol, magnesium sulfate, and remifentanyl are among the most commonly studied agents, each exhibiting distinct pharmacological profiles and clinical effects (3-6). Several randomized clinical trials and comparative studies have investigated these drugs, focusing on outcomes such as intraoperative bleeding, postoperative edema, and ecchymosis (7-10). Moreover, recent systematic reviews and meta-analyses have synthesized the evidence to guide anesthetic practice in nasal surgeries (11). Given the clinical importance of controlled hypotension and the diversity of available techniques, this narrative review aims to provide a comprehensive overview of the underlying mechanisms, common methods, and clinical considerations for implementing controlled hypotension in rhinoplasty.

Mechanisms of Controlled Hypotension

Controlled hypotension refers to the intentional reduction of systemic arterial blood pressure to a level that decreases bleeding during surgery while maintaining adequate tissue perfusion and oxygenation. The primary mechanism by which controlled hypotension reduces bleeding is by lowering the mean arterial pressure (MAP), thereby decreasing blood flow and capillary hydrostatic pressure in the surgical field. This leads to reduced capillary bleeding and improved visibility for the surgeon (2).

The reduction in blood pressure also minimizes the perfusion pressure within the fragile and highly vascularized nasal mucosa, which is particularly susceptible to bleeding during rhinoplasty. Moreover, decreased venous pressure contributes to less venous oozing, further enhancing the clarity of the operative field (1).

Pharmacologically, different agents achieve hypotension through diverse pathways. For instance, dexmedetomidine is an alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and sympatholysis, leading to reduced norepinephrine release and

consequent lowering of blood pressure and heart rate (3,4). Esmolol, a selective beta-1 adrenergic blocker, decreases cardiac output by reducing heart rate and myocardial contractility, thereby lowering blood pressure without significant vasodilation (3, 5).

Magnesium sulfate induces vasodilation by antagonizing calcium channels in vascular smooth muscle cells, resulting in decreased peripheral vascular resistance and hypotension (6, 7). Remifentanyl, a short-acting opioid, contributes to hypotension primarily by attenuating sympathetic nervous system activity and causing vasodilation (8).

Overall, the careful selection and combination of these agents can tailor the hypotensive state to the patient's clinical condition and surgical requirements, balancing the need for reduced bleeding with the preservation of vital organ perfusion.

Techniques of Controlled Hypotension

Controlled hypotension can be achieved through various pharmacological and non-pharmacological methods. The choice of technique depends on patient factors, surgical requirements, and anesthesiologist preference. Pharmacologically, several agents have been extensively studied for inducing controlled hypotension during rhinoplasty. Dexmedetomidine, an alpha-2 adrenergic agonist, provides sedation, analgesia, and sympatholytic effects, resulting in a gradual and controllable decrease in blood pressure and heart rate (3,4). Its benefits include stable hemodynamics and reduced anesthetic requirements.

Esmolol, a short-acting selective beta-1 blocker, reduces heart rate and myocardial contractility, effectively lowering blood pressure without causing significant vasodilation. It has a rapid onset and short duration, making it suitable for intraoperative blood pressure control (3, 5).

Magnesium sulfate works by blocking calcium channels in vascular smooth muscles, leading to vasodilation and decreased peripheral vascular

resistance. This agent not only helps in blood pressure reduction but may also have neuroprotective and antiarrhythmic properties (6, 7).

Remifentanyl, an ultra-short-acting opioid, attenuates sympathetic nervous system activity and causes peripheral vasodilation, thereby facilitating controlled hypotension. Its rapid metabolism allows for precise titration during surgery (8). Non-pharmacological approaches include optimizing patient positioning, ventilation strategies, and depth of anesthesia to complement pharmacological methods. For example, moderate hyperventilation leading to mild hypocapnia can induce vasoconstriction and reduce bleeding. Additionally, elevating the head of the bed may decrease venous pressure in the surgical site (2). In clinical practice, these agents are often used in

combination to achieve optimal hypotension with minimal side effects. The choice and dosing require careful titration guided by continuous hemodynamic monitoring to maintain tissue perfusion and prevent ischemic complications.

To facilitate clinical decision-making, Table 1 provides a comprehensive comparison of commonly utilized pharmacological agents for inducing controlled hypotension in rhinoplasty, detailing their mechanisms of action, dosing regimens, therapeutic advantages, adverse effect profiles, and pertinent clinical considerations. Subsequently, Table 2 delineates a stepwise algorithm to assist anesthesiologists in selecting and titrating appropriate hypotensive strategies tailored to individual patient characteristics and surgical requirements.

Table 1. Comparison of Common Agents Used for Controlled Hypotension in Rhinoplasty

Agent	Mechanism of Action	Typical Dose (IV)	Advantages	Common Side Effects	Clinical Considerations
Dexmedetomidine	Alpha-2 adrenergic agonist; reduces sympathetic outflow	Loading: 1 µg/kg over 10 min; Maintenance: 0.2–0.7 µg/kg/hr infusion	Provides sedation, analgesia, stable hemodynamics, reduces anesthetic needs (3,4)	Bradycardia, hypotension	Useful for stable, gradual BP control; monitor HR carefully (4,11)
Esmolol	Selective beta-1 blocker; decreases HR and contractility	Bolus: 500 µg/kg; infusion: 50–300 µg/kg/min	Rapid onset/offset, easy titration (3,5)	Hypotension, bradycardia	Suitable for short procedures or quick BP adjustments (5)
Magnesium sulfate	Calcium channel antagonist; causes vasodilation	Bolus: 30–50 mg/kg; infusion: 6–20 mg/kg/hr	Vasodilation, neuroprotective effects (6,7)	Flushing, hypotension, muscle weakness	Useful adjunct; monitor for side effects (7)
Remifentanyl	Ultra-short-acting opioid; reduces sympathetic tone	Infusion: 0.1–2 µg/kg/min	Rapid titration, potent hypotension (8,10)	Respiratory depression, bradycardia	Requires careful dosing and monitoring (8,10)

Table 2. Algorithm for Controlled Hypotension in Rhinoplasty

1. Preoperative Assessment	
○	Evaluate cardiovascular status
○	Identify contraindications (severe cardiac/cerebrovascular disease)
2. Agent Selection	
○	Stable patient, longer surgery → Dexmedetomidine
○	Need rapid BP control → Esmolol or Remifentanyl
○	Adjunct therapy or neuroprotection → Magnesium sulfate
3. Intraoperative Management	
○	Initiate selected agent with appropriate dosing
○	Continuous hemodynamic monitoring (BP, HR, oxygenation)
○	Maintain MAP between 50-65 mmHg unless contraindicated
4. Adjust Therapy	
○	Titrate drug dose based on BP and clinical response
○	Manage side effects promptly
5. Postoperative Care	
○	Monitor for neurological and cardiovascular complications
○	Assess for bleeding, edema, ecchymosis

Clinical Considerations

Implementing controlled hypotension during rhinoplasty requires careful attention to patient safety and individualized anesthetic management. The goal is to lower blood pressure sufficiently to reduce bleeding while preserving adequate organ perfusion.

Continuous monitoring of vital signs, including invasive or non-invasive blood pressure, heart rate, oxygen saturation, and, when available, cardiac output, is essential to promptly detect and manage hemodynamic instability (2). Target mean arterial pressure is commonly maintained between 50 and 65 mmHg, though patient factors may necessitate adjustments.

Patient selection is critical. Controlled hypotension is generally contraindicated in patients with significant cardiovascular disease, cerebrovascular pathology, or compromised organ perfusion. Preoperative evaluation

should identify such risks to prevent adverse outcomes (2).

Potential complications include ischemia of vital organs, prolonged hypotension, and delayed emergence from anesthesia. Choice of hypotensive agents must balance efficacy with safety, considering factors like duration of surgery and patient comorbidities (4,6).

Postoperative monitoring should focus on neurological status, cardiovascular stability, and wound healing. Early recognition of complications such as hematoma or excessive edema allows timely intervention, improving surgical outcomes (7,8).

In summary, controlled hypotension is a valuable tool in rhinoplasty anesthesia when applied judiciously with appropriate monitoring and patient selection.

Clinical Outcomes and Effectiveness of Controlled Hypotension in Rhinoplasty

Controlled hypotension has been shown to significantly improve surgical conditions during rhinoplasty by reducing intraoperative bleeding and enhancing the surgeon's visibility. Studies consistently report that maintaining a lowered blood pressure reduces blood loss, shortens operative time, and may contribute to better aesthetic outcomes (1,7,8).

Dexmedetomidine, among the commonly used agents, not only facilitates effective blood pressure control but also provides additional benefits such as sedation and analgesia, leading to decreased requirements for other anesthetics and opioids (4,11). Clinical trials comparing dexmedetomidine with remifentanyl or magnesium sulfate have demonstrated favorable hemodynamic stability and reduced bleeding with dexmedetomidine (4,9,10).

Esmolol offers rapid and controllable blood pressure reduction, making it a suitable agent in shorter procedures or when quick adjustments are needed (3,5). Magnesium sulfate's vasodilatory properties and potential neuroprotective effects make it a valuable adjunct, although its use may be limited by side effects like hypotension and flushing (6,7).

Remifentanyl's ultra-short action allows for fine-tuning of hemodynamics, but its potent opioid effects necessitate careful dosing to avoid respiratory depression (8,10).

Overall, the choice of agent and technique should be individualized, balancing efficacy, safety, and the patient's clinical condition. While controlled hypotension improves operative field conditions, anesthesiologists must remain vigilant to avoid complications related to excessive hypotension.

Limitations and Controversies

Controlled hypotension has demonstrated clear benefits in improving surgical field visibility and reducing blood loss during rhinoplasty; however, several limitations and ongoing controversies merit consideration.

Firstly, there is notable heterogeneity in the protocols used across studies, including varying target mean arterial pressures (MAP) typically ranging from 50 to 65 mmHg, and differences in the duration and timing of hypotensive periods (2,6,7). This lack of standardized guidelines complicates direct comparisons and clinical decision-making.

Secondly, while pharmacologic agents such as dexmedetomidine, remifentanyl, and magnesium sulfate have been studied extensively, their comparative efficacy and safety profiles remain uncertain. Recent randomized controlled trials have provided promising but sometimes inconsistent results due to small sample sizes and varying methodologies (4,8,9,12). For example, dexmedetomidine effectively reduces intraoperative bleeding but is often associated with bradycardia and prolonged sedation, which may delay postoperative recovery and necessitate additional interventions (4,12). Conversely, remifentanyl allows rapid titration and recovery but carries the risk of opioid-related adverse effects including respiratory depression (8,13).

The adjunctive use of magnesium sulfate remains controversial; although it may enhance hypotensive effects and improve surgical field quality, some studies report increased requirements for vasoactive agents and possible side effects (7,9,12). Therefore, the choice and combination of agents should be tailored to individual patient characteristics and surgical context.

Importantly, most investigations focus on immediate intraoperative and early postoperative outcomes such as blood loss, edema, and operative field clarity, with a paucity of data on long-term neurological and cognitive effects, organ perfusion, and patient-reported outcomes (1,11,15). Given that rhinoplasty is often performed on otherwise healthy individuals, careful attention to safety and functional outcomes is essential.

Finally, patient-specific factors including baseline cardiovascular status, autonomic regulation, and comorbidities significantly influence the safety and effectiveness of controlled hypotension, underscoring the need for individualized anesthetic management and vigilant intraoperative monitoring (1,11).

In summary, although controlled hypotension is a valuable anesthetic technique in rhinoplasty, the variability in protocols, side-effect profiles, and insufficient long-term data highlight the urgent need for large, well-designed multicenter trials and development of standardized clinical guidelines.

Future Perspectives

Controlled hypotension has demonstrated clear benefits in rhinoplasty by reducing intraoperative bleeding and improving surgical visibility. However, there is still a need for refinement in its application. Future studies should aim to define optimal target mean arterial pressures in different patient populations, particularly in those with comorbidities such as hypertension or cerebrovascular disease. Moreover, comparative studies on the safety and effectiveness of different pharmacologic agents—including newer vasodilators, α_2 -agonists, and β -blockers—are needed to determine the most favorable drug combinations with minimal hemodynamic instability.

Advances in intraoperative monitoring, including the use of near-infrared spectroscopy (NIRS) and depth-of-anesthesia monitoring (e.g., BIS), may offer more precise assessment of cerebral and systemic perfusion during induced hypotension. Future research may also explore individualized approaches that integrate patient-specific factors such as age, baseline blood pressure, and anesthetic risk into hypotension protocols.

Developing standardized guidelines based on high-quality evidence will ultimately help anesthesiologists implement controlled

hypotension more safely and effectively across a wider range of surgical settings.

Methods

This study was designed as a narrative review. In this approach, the focus is on summarizing, synthesizing, and critically analyzing the available literature to provide a comprehensive understanding of controlled hypotension in rhinoplasty.

Relevant studies were identified through searches in PubMed, Scopus, Web of Science, and Google Scholar using combinations of the following keywords: “controlled hypotension,” “rhinoplasty,” “dexmedetomidine,” “remifentanyl,” “magnesium sulfate,” “intraoperative bleeding,” and “anesthetic techniques.”

Unlike systematic reviews, this narrative review did not apply rigid inclusion or exclusion criteria or independent multi-reviewer screening. Instead, priority was given to key clinical trials, comparative studies, and meta-analyses published between 2000 and 2024 that provided insights into mechanisms, pharmacologic strategies, and clinical considerations of controlled hypotension in rhinoplasty. Both English and Persian articles were considered.

Data from selected studies were qualitatively analyzed and summarized, with emphasis on clinical relevance, strengths and limitations of evidence, and applicability to perioperative practice. No formal statistical pooling or meta-analysis was performed, consistent with the narrative review design.

Discussion

Controlled hypotension is an established anesthetic technique aimed at reducing intraoperative bleeding and improving the surgical field during rhinoplasty. The reviewed evidence consistently demonstrates that lowering mean arterial pressure to a moderate degree (usually between 50 to 65 mmHg) contributes to decreased blood loss,

reduced tissue edema, and enhanced visibility for the surgeon (1,2). This translates to shorter operative times and potentially better surgical outcomes.

Pharmacologic agents used to induce controlled hypotension—most notably dexmedetomidine, remifentanyl, and magnesium sulfate—offer varying benefits and limitations. Dexmedetomidine, a selective α_2 -adrenoceptor agonist, has gained popularity due to its sedative, analgesic, and sympatholytic properties, allowing effective blood pressure reduction without compromising respiratory function (4,6). However, its association with bradycardia and prolonged sedation requires cautious titration and monitoring (4,12). Remifentanyl, an ultra-short-acting opioid, facilitates rapid onset and recovery, yet carries risks of opioid-related side effects such as respiratory depression and postoperative nausea (8,13). Magnesium sulfate, often used as an adjunct, may potentiate hypotensive effects and improve the surgical field, but evidence regarding its optimal dosing and side-effect profile remains mixed (7,9,12).

The heterogeneity in clinical protocols, including drug choice, dosing regimens, and blood pressure targets, challenges the development of standardized guidelines. Moreover, most studies focus on immediate surgical outcomes, with limited data on long-term patient-centered endpoints such as cognitive function, organ perfusion, and quality of recovery (1,11,15). This gap is particularly relevant given the elective nature of rhinoplasty and the generally healthy patient population, for whom minimizing perioperative risks is paramount.

Future research should prioritize large-scale, multicenter randomized trials comparing different hypotensive agents and protocols, with standardized outcome measures encompassing both intraoperative parameters and long-term functional recovery. Additionally, the integration of individualized

anesthesia plans considering patient comorbidities and intraoperative hemodynamic monitoring may optimize safety and efficacy.

In conclusion, controlled hypotension remains a valuable strategy in rhinoplasty, improving surgical conditions and reducing bleeding. Nonetheless, careful consideration of agent selection, dose titration, and patient-specific factors is essential to maximize benefits while minimizing risks. Ongoing research will further refine practice guidelines and enhance perioperative care in this field.

Conclusion

Controlled hypotension is an effective anesthetic technique widely employed in rhinoplasty to improve surgical field visibility, minimize intraoperative blood loss, and potentially shorten operative duration. The choice of pharmacologic agents—primarily dexmedetomidine, remifentanyl, and magnesium sulfate—must be individualized based on their distinct efficacy profiles and side effect risks. While dexmedetomidine offers superior hemodynamic stability and sedative benefits, its association with bradycardia and delayed recovery necessitates careful monitoring. Remifentanyl provides rapid titratability but carries opioid-related complications. Magnesium sulfate, as an adjunct, can enhance hypotensive effects but requires further evaluation regarding optimal use.

Despite consistent evidence supporting short-term advantages, substantial heterogeneity in protocols and limited data on long-term safety and patient-centered outcomes remain challenges. This underscores the critical need for standardized guidelines based on robust multicenter randomized trials and comprehensive assessment frameworks that include neurocognitive, cardiovascular, and quality-of-life endpoints.

In clinical practice, implementing controlled hypotension should involve thorough patient

assessment, vigilant intraoperative monitoring, and tailored anesthetic plans to balance efficacy and safety. Future advances integrating multimodal monitoring and individualized pharmacologic strategies hold promise for optimizing outcomes.

In summary, controlled hypotension is a valuable component of anesthetic management in rhinoplasty but requires careful application grounded in evolving evidence to maximize benefits and minimize potential harms.

Acknowledgments

Thank you to Brandon Sum for your role in conceptualizing and reviewing this work.

Conflicts of Interest

The authors declare no conflicts of interest.

Financial Support

Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, financially supported this work.

Authors ORCIDs

Hamidreza Azizi Farsani

<https://orcid.org/0000-0002-4561-6066>

Zahra Abbasi

<https://orcid.org/0009-0007-2486-8698>

Hasanali Ahmadi

<https://orcid.org/0000-0001-9188-2616>

Sogol Asgari

<https://orcid.org/0000-0001-7837-8888>

References

- 1.Ozgur A, et al. Effectiveness of controlled hypotension on surgical field quality in rhinoplasty. *J Craniofac Surg.* 2014;25(3):e285–e288.
- 2.Degoute CS. Controlled hypotension: a guide to drug choice. *Drugs.* 2007;67(7):1053–1076.
- 3.Yuksel A, et al. Controlled hypotension for functional endoscopic sinus surgery: comparison of esmolol and dexmedetomidine. *Eur J Anaesthesiol.* 2008;25(6):517–523.
- 4.Ghodraty MR, et al. Comparison of dexmedetomidine vs. propofol-remifentanyl in

controlled hypotension for rhinoplasty. *Adv Biomed Res.* 2015;4:50.

5.Memiş D, et al. Dexmedetomidine vs esmolol for controlled hypotension during tympanoplasty or septorhinoplasty. *J Clin Anesth.* 2008;20(2):155–159.

6.Elsharnouby NM, et al. Magnesium sulfate as an adjuvant in controlled hypotension. *Anesth Analg.* 2006;102(3):729–735.

7.Lu Z, et al. Effects of perioperative magnesium sulfate with controlled hypotension on intraoperative bleeding and postoperative ecchymosis and edema in open rhinoplasty. *Am J Otolaryngol.* 2020.

8.Koşucu M, et al. Effects of perioperative remifentanyl with controlled hypotension on intraoperative bleeding and postoperative edema and ecchymosis in open rhinoplasty. *J Craniofac Surg.* 2014.

9.Comparative Study Between Dexmedetomidine Versus Magnesium Sulfate for Controlled Hypotensive Anesthesia in Rhinoplasty Surgeries. *Anaesthesia, Pain & Intensive Care.* 2024.

10.Comparison of the Effect of Dexmedetomidine and Remifentanyl on Controlled Hypotension During Rhinoplasty: A Clinical Trial Study. *J Craniofac Surg.* 2021.

11.Janipour M, Owji SH, et al. Dexmedetomidine versus remifentanyl in nasal surgery: a systematic review and meta analysis. *BMC Anesthesiol.* 2024.

12.Abd Elhalem SAA, El Shawarby AE, Youssef KYK. Dexmedetomidine versus magnesium sulfate for controlled hypotension during rhinoplasty: a randomized comparative study. *Anaesthesia Pain & Intensive Care.* 2024;28(5):894–900. Lippincott Journals+15ApiCare Online+15Al-Rafidain Journal of Medical Sciences+15PubMed+1PMC+1

13.Xu N, Chen L, Liu L, Rong W. Dexmedetomidine versus remifentanyl for controlled hypotension: a systematic review and meta analysis. *PLoS One.* 2023;18(1):e0278846. PubMed

14.Al Rafidain AJMS Study Group. Remifentanyl vs nitroglycerin in controlled hypotension for rhinoplasty: randomized comparative trial. *Al Rafidain J Med Sci.* 2024;15(4):123–130. Al-Rafidain Journal of Medical Sciences

15. Dauterman L, Khan N, Tebbe C, Li J, Sun Y, Gunderman D, Liu Z, Adams DC, Sessler DI, Meng L. Efficacy and safety of intraoperative controlled hypotension: a systematic review and meta-analysis of randomised trials. *Br J Anaesth.* 2024 Nov;133(5):940–954. doi:10.1016/j.bja.2024.06.008